We are devoted to the challenging task of developing innovative solutions for an enhanced clinical management of patients who suffer from highly prevalent neurological diseases such as stroke and Alzheimer’s disease.
Our first product Minerva, consists of a clinical decision support system (CDSS) that provides useful insights to clinicians for an enhanced clinical management of stroke patients.
We are developing the next generation of monoclonal antibodies (with high affinity to several Tau aberrant species) with multiple applications in the diagnosis and treatment of AD. Our first product in this field is a novel ELISA kit to detect misfolded proteins in Cerebrospinal fluid (CSF), thus allowing diagnosis of the disease even at its subclinical stage. Early diagnosis of AD is essential to improve patients’ prognosis.